Component

Cannabidiol

Species, preparation, dose and limitations are retained on linked claims.

4 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Evidence emerged that cannabidiol partially inhibits the CYP2C-catalysed hydroxylation of THC to 11-OH-THC, with the probability particularly high for oral intake, but the effect was small compared with the variability caused by other factors, and significantly higher exposure and shorter time to peak were found in women than men.

    Cannabidiol → Hydroxylation of THC to 11-OH-THC source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/thc-research/16306858.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "686c5587340a5590db33367328f93f4be704262c3d92b53f627ff01b154943da", "start_char": 0, "end_char": 2129, "text_sha256": "686c5587340a5590db33367328f93f4be704262c3d92b53f627ff01b154943da"}
    experimental_model
    Randomised double-blind placebo-controlled crossover in 24 volunteers
    exposure
    Oral THC 10 mg versus cannabis extract containing 10 mg THC plus 5.4 mg cannabidiol
    limitations
    A human randomised crossover. The authors conclude the cannabidiol effect is small relative to other variability, so a pharmacokinetic explanation for extract-versus-THC differences is improbable at these doses.
    nutrient_topic
    THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. · Delta-9-tetrahydrocannabinol / THC
    organism
    Human
    plain_language
    Cannabidiol does slow one step of THC breakdown, but not enough to explain much.
    primary_references
    [thc-p16306858] Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. (2005). https://pubmed.ncbi.nlm.nih.gov/16306858/ DOI: 10.1097/01.ftd.0000177223.19294.5c
    tissue_or_cell_type
    Plasma

    THC: the cannabinoid receptors, the endocannabinoid system it occupies, what the drug does, and the dietary fat it is built from (2026-09-21) · lines 556–567

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Randomised double-blind placebo-controlled crossover in 24 volunteers · source_derived_draft · unverified_draft

    ### thc-cbd-inhibits-hydroxylation Evidence emerged that cannabidiol partially inhibits the CYP2C-catalysed hydroxylation of THC to 11-OH-THC, with the probability particularly high for oral intake, but the effect was small compared with the variability caused by other factors, and significantly higher exposure and shorter time to peak were found in women than men. Condition category: normal nutrient_topic: THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. plain_language: Cannabidiol does slow one step of THC breakdown, but not enough to explain much. organism: Human tissue_or_cell_type: Plasma experimental_model: Randomised double-blind placebo-controlled crossover in 24 volunteers limitations: A human randomised crossover. The authors conclude the cannabidiol effect is small relative to other variability, so a pharmacokinetic explanation for extract-versus-THC differences is improbable at these doses. exposure: Oral THC 10 mg versus cannabis extract containing 10 mg THC plus 5.4 mg cannabidiol evidence_span: {"source_cache": "artifacts/thc-research/16306858.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "686c5587340a5590db33367328f93f4be704262c3d92b53f627ff01b154943da", "start_char": 0, "end_char": 2129, "text_sha256": "686c5587340a5590db33367328f93f4be704262c3d92b53f627ff01b154943da"} [thc-p16306858] Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. (2005). https://pubmed.ncbi.nlm.nih.gov/16306858/ DOI: 10.1097/01.ftd.0000177223.19294.5c
    Complete structured claim and evidence

  2. Cannabidiol pretreatment potentiated blood and brain THC levels with both acute and chronic administration in adolescent rats, potentiated the inhibition of body weight gain caused by chronic THC, and mildly augmented its anxiogenic, locomotor-suppressant and social-interaction effects.

    Cannabidiol → Brain THC concentration source_derived_draftungraded
    Experimental context and source evidence
    evidence_span
    {"source_cache": "artifacts/thc-research/21667074.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "da582d1624586305da4993ae0e27e4d07352e46eda2ac97c88cc924f2a8ed598", "start_char": 0, "end_char": 1688, "text_sha256": "da582d1624586305da4993ae0e27e4d07352e46eda2ac97c88cc924f2a8ed598"}
    experimental_model
    Adolescent rats given ascending THC doses over 21 days with and without equivalent cannabidiol
    exposure
    Ascending THC 1 to 10 mg/kg over 21 days with cannabidiol pretreatment
    limitations
    A chronic animal study at equivalent doses, reaching the opposite conclusion to the human single-dose work on whether cannabidiol opposes THC.
    nutrient_topic
    THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. · Delta-9-tetrahydrocannabinol / THC
    organism
    Rat
    plain_language
    In young rats cannabidiol made THC stronger, not weaker.
    primary_references
    [thc-p21667074] Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. (2011). https://pubmed.ncbi.nlm.nih.gov/21667074/ DOI: 10.1007/s00213-011-2342-0
    tissue_or_cell_type
    Blood, brain and behaviour

    THC: the cannabinoid receptors, the endocannabinoid system it occupies, what the drug does, and the dietary fat it is built from (2026-09-21) · lines 569–580

    AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Adolescent rats given ascending THC doses over 21 days with and without equivalent cannabidiol · source_derived_draft · unverified_draft

    ### thc-cbd-potentiates-thc Cannabidiol pretreatment potentiated blood and brain THC levels with both acute and chronic administration in adolescent rats, potentiated the inhibition of body weight gain caused by chronic THC, and mildly augmented its anxiogenic, locomotor-suppressant and social-interaction effects. Condition category: normal nutrient_topic: THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates. plain_language: In young rats cannabidiol made THC stronger, not weaker. organism: Rat tissue_or_cell_type: Blood, brain and behaviour experimental_model: Adolescent rats given ascending THC doses over 21 days with and without equivalent cannabidiol limitations: A chronic animal study at equivalent doses, reaching the opposite conclusion to the human single-dose work on whether cannabidiol opposes THC. exposure: Ascending THC 1 to 10 mg/kg over 21 days with cannabidiol pretreatment evidence_span: {"source_cache": "artifacts/thc-research/21667074.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "da582d1624586305da4993ae0e27e4d07352e46eda2ac97c88cc924f2a8ed598", "start_char": 0, "end_char": 1688, "text_sha256": "da582d1624586305da4993ae0e27e4d07352e46eda2ac97c88cc924f2a8ed598"} [thc-p21667074] Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. (2011). https://pubmed.ncbi.nlm.nih.gov/21667074/ DOI: 10.1007/s00213-011-2342-0
    Complete structured claim and evidence

  3. Cannabidiol plus moringin, each at 5 micromolar, produced larger changes in inflammatory, oxidative and apoptosis markers in LPS-stimulated murine macrophages than either constituent alone at that concentration.

    Cannabidiol → Moringin / MIC-1 source_derived_draftungraded
    Experimental context and source evidence
    dose
    Cannabidiol 5 micromolar plus moringin 5 micromolar
    duration
    Acute
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    LPS-stimulated murine macrophages
    limitations
    This cell combination result does not establish clinical synergy, safety or dosing and should not be extrapolated to cannabis or whole Moringa products.
    nutrient_topic
    Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
    organism
    LPS-stimulated murine macrophages
    plain_language
    Cannabidiol plus moringin, each at 5 micromolar, produced larger changes in inflammatory, oxidative and apoptosis markers in LPS-stimulated murine macrophages than either constituent alone at that concentration.
    primary_references
    Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages. (2016). https://pubmed.ncbi.nlm.nih.gov/27215129/ DOI: 10.1016/j.fitote.2016.05.008
    route
    In vitro
    tissue
    TNF-alpha, IL-10, iNOS, NRF2, nitrotyrosine, BCL2, BAX and cleaved-caspase-3 panel

    Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 90–99

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · LPS-stimulated murine macrophages · source_derived_draft · unverified_draft

    ## moringa-cannabidiol-combination Cannabidiol plus moringin, each at 5 micromolar, produced larger changes in inflammatory, oxidative and apoptosis markers in LPS-stimulated murine macrophages than either constituent alone at that concentration. Model/species: LPS-stimulated murine macrophages Tissue/system: TNF-alpha, IL-10, iNOS, NRF2, nitrotyrosine, BCL2, BAX and cleaved-caspase-3 panel Exposure: Cannabidiol 5 micromolar plus moringin 5 micromolar Route: In vitro Duration: Acute Limits: This cell combination result does not establish clinical synergy, safety or dosing and should not be extrapolated to cannabis or whole Moringa products. Primary reference: Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages. (2016). https://pubmed.ncbi.nlm.nih.gov/27215129/ DOI: 10.1016/j.fitote.2016.05.008 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

Where it participates (unsigned role)

  1. A TRPV1 antagonist impaired cannabidiol efficacy in the macrophage assay but did not alter moringin activity; CB1 and CB2 antagonists affected neither route.

    Human transient receptor potential vanilloid 1 / TRPV1 → TRPV1-sensitive cannabidiol efficacy but TRPV1-insensitive moringin efficacy in macrophages source_derived_draftungraded
    Experimental context and source evidence
    dose
    Cannabidiol or moringin with TRPV1, CB1 or CB2 antagonists
    duration
    Acute
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    LPS-stimulated murine macrophages
    limitations
    The abstract does not establish direct binding of either compound to every tested receptor, and the result is not a clinical interaction.
    nutrient_topic
    Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
    organism
    LPS-stimulated murine macrophages
    plain_language
    A TRPV1 antagonist impaired cannabidiol efficacy in the macrophage assay but did not alter moringin activity; CB1 and CB2 antagonists affected neither route.
    primary_references
    Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages. (2016). https://pubmed.ncbi.nlm.nih.gov/27215129/ DOI: 10.1016/j.fitote.2016.05.008
    route
    In vitro perturbation
    tissue
    Receptor-antagonist separation of combination components

    Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 101–110

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · LPS-stimulated murine macrophages · source_derived_draft · unverified_draft

    ## moringa-cannabidiol-trpv1-separation A TRPV1 antagonist impaired cannabidiol efficacy in the macrophage assay but did not alter moringin activity; CB1 and CB2 antagonists affected neither route. Model/species: LPS-stimulated murine macrophages Tissue/system: Receptor-antagonist separation of combination components Exposure: Cannabidiol or moringin with TRPV1, CB1 or CB2 antagonists Route: In vitro perturbation Duration: Acute Limits: The abstract does not establish direct binding of either compound to every tested receptor, and the result is not a clinical interaction. Primary reference: Anti-inflammatory and antioxidant effects of a combination of cannabidiol and moringin in LPS-stimulated macrophages. (2016). https://pubmed.ncbi.nlm.nih.gov/27215129/ DOI: 10.1016/j.fitote.2016.05.008 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards